516 related articles for article (PubMed ID: 26106076)
1. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.
Lu S; Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Li Z; Wu JD
Clin Cancer Res; 2015 Nov; 21(21):4819-30. PubMed ID: 26106076
[TBL] [Abstract][Full Text] [Related]
2. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Basher F; Jeng EK; Wong H; Wu J
Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
[TBL] [Abstract][Full Text] [Related]
3. Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.
Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Graff JN; Li Z; Wu JD
Sci Adv; 2017 May; 3(5):e1602133. PubMed ID: 28560327
[TBL] [Abstract][Full Text] [Related]
4. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
[TBL] [Abstract][Full Text] [Related]
5. S100A4-neutralizing antibody suppresses spontaneous tumor progression, pre-metastatic niche formation and alters T-cell polarization balance.
Grum-Schwensen B; Klingelhöfer J; Beck M; Bonefeld CM; Hamerlik P; Guldberg P; Grigorian M; Lukanidin E; Ambartsumian N
BMC Cancer; 2015 Feb; 15():44. PubMed ID: 25884510
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
7. Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer.
Wu J
Oncoimmunology; 2016 Mar; 5(3):e1095434. PubMed ID: 27141357
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
John LB; Devaud C; Duong CP; Yong CS; Beavis PA; Haynes NM; Chow MT; Smyth MJ; Kershaw MH; Darcy PK
Clin Cancer Res; 2013 Oct; 19(20):5636-46. PubMed ID: 23873688
[TBL] [Abstract][Full Text] [Related]
9. Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC
Zhang J; Larrocha PS; Zhang B; Wainwright D; Dhar P; Wu JD
J Immunother Cancer; 2019 Aug; 7(1):223. PubMed ID: 31446896
[TBL] [Abstract][Full Text] [Related]
10. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity.
Märten A; von Lilienfeld-Toal M; Büchler MW; Schmidt J
Int J Cancer; 2006 Nov; 119(10):2359-65. PubMed ID: 16929491
[TBL] [Abstract][Full Text] [Related]
11. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
[TBL] [Abstract][Full Text] [Related]
12. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
[TBL] [Abstract][Full Text] [Related]
13. RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.
Yin X; Luistro L; Zhong H; Smith M; Nevins T; Schostack K; Hilton H; Lin TA; Truitt T; Biondi D; Wang X; Packman K; Rosinski J; Berkofsky-Fessler W; Tang JP; Pant S; Geho D; Vega-Harring S; Demario M; Levitsky H; Simcox M
Clin Cancer Res; 2013 Oct; 19(20):5686-98. PubMed ID: 23974006
[TBL] [Abstract][Full Text] [Related]
14. The activating rat Ly49s5 receptor responds to increased levels of MHC class Ib molecules on Listeria monocytogenes-infected enteric epithelial cells.
Shegarfi H; Dai KZ; Inngjerdingen M; Ryan JC; Vaage JT; Rolstad B; Naper C
Eur J Immunol; 2010 Dec; 40(12):3535-43. PubMed ID: 21108473
[TBL] [Abstract][Full Text] [Related]
15. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
[TBL] [Abstract][Full Text] [Related]
16. Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype.
Xiao G; Wang X; Sheng J; Lu S; Yu X; Wu JD
J Hematol Oncol; 2015 Feb; 8():13. PubMed ID: 25887583
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
18. Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.
Battella S; Cox MC; Santoni A; Palmieri G
J Leukoc Biol; 2016 Jan; 99(1):87-96. PubMed ID: 26136506
[TBL] [Abstract][Full Text] [Related]
19. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
20. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
